Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (311-320 of 379) with videos related to

Pageof 38
Sort By:
Neuro-Oncology|February 18, 2010
Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphomaHendrik Pels, Annika Juergens, Isabell Schirgens, et al.
British Journal of Haematology|November 14, 2013
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphomaMichelle Fanale, Sarit Assouline, John Kuruvilla, et al.
Blood|October 9, 2013
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)Sylvia Hartmann, Dennis A Eichenauer, Annette Plütschow, et al.
Advances in Radiation Oncology|March 10, 2023
Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern EraMichael Oertel, Dominik Hering, Nina Nacke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2020
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study GroupStefanie Kreissl, Horst Müller, Helen Goergen, et al.
Infection|February 19, 2022
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphomaAnne Sophie Jacob, Helen Kaul, Michael Fuchs, et al.
British Journal of Haematology|September 14, 2021
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trialElena Gerhard-Hartmann, Helen Goergen, Paul J Bröckelmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter studyMarcus Hentrich, Marcel Berger, Christoph Wyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2010
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphomaAndreas Josting, Horst Müller, Peter Borchmann, et al.
Leukemia & Lymphoma|July 18, 2022
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trialStephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, et al.
Pageof 38

Showing results (311-320 of 379) with videos related to

Sort By:
Pageof 38
Neuro-Oncology|February 18, 2010
Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphomaHendrik Pels, Annika Juergens, Isabell Schirgens, et al.
British Journal of Haematology|November 14, 2013
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphomaMichelle Fanale, Sarit Assouline, John Kuruvilla, et al.
Blood|October 9, 2013
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)Sylvia Hartmann, Dennis A Eichenauer, Annette Plütschow, et al.
Advances in Radiation Oncology|March 10, 2023
Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern EraMichael Oertel, Dominik Hering, Nina Nacke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2020
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study GroupStefanie Kreissl, Horst Müller, Helen Goergen, et al.
Infection|February 19, 2022
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphomaAnne Sophie Jacob, Helen Kaul, Michael Fuchs, et al.
British Journal of Haematology|September 14, 2021
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trialElena Gerhard-Hartmann, Helen Goergen, Paul J Bröckelmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter studyMarcus Hentrich, Marcel Berger, Christoph Wyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2010
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphomaAndreas Josting, Horst Müller, Peter Borchmann, et al.
Leukemia & Lymphoma|July 18, 2022
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trialStephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, et al.
Pageof 38